FAQ on NanoViricides' NV-387 Antiviral Program and Phase II Trials
Summary
What is NV-387 and what makes it significant?
NV-387 is NanoViricides’ broad-spectrum antiviral drug candidate that has shown superior activity in animal models compared to approved antivirals for COVID, influenza, RSV, and smallpox, indicating its potential as a versatile and effective treatment for multiple viral infections.
What progress has NanoViricides made with NV-387?
The company has received clearance from the DRC’s National Ethics Committee to submit a Phase II trial application for MPox and is initiating programs targeting measles and avian flu, following a successful Phase I trial with no adverse events.
How does NV-387 compare to existing antiviral treatments?
NV-387 has demonstrated superior activity in animal models against several viruses compared to currently approved antivirals, suggesting it could offer more effective treatment options for diseases like COVID-19, influenza, RSV, and smallpox.
What are the financial standings of NanoViricides?
As of Q1 2025, NanoViricides reported $2.73 million in cash, $6.98 million in property and equipment, and $1.2 million in current liabilities, but noted the need for additional funding to support operations beyond early 2026.
Where can I find more information about NanoViricides and its programs?
For more information, visit NanoViricides’ website at www.NanoViricides.com or the company’s newsroom at https://ibn.fm/NNVC.
What is the next step for NV-387?
NanoViricides is currently focused on advancing NV-387 into Phase II human clinical trials for various viral infections, including MPox, measles, and avian flu, building on its successful Phase I outcomes.
Who is involved in the development of NV-387?
NanoViricides is developing NV-387 in collaboration with TheraCour Pharma, Inc., under a Memorandum of Understanding for the development of drugs based on nanoviricide technology for antiviral infections, excluding cancer and similar diseases.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 113002